Sandbox Turky2: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(5 intermediate revisions by the same user not shown)
Line 1: Line 1:
{| border="1"
{| class="wikitable"
|+ The table's caption
! style="text-align: center;" | Rank
! Column heading 1 !! Column heading 2 !! Column heading 3
! style="text-align: center; font-weight: bold;" | Journal
! style="text-align: center; font-weight: bold;" | Website
! style="text-align: center; font-weight: bold;" | Impact Factor
|-
|-
! Row heading 1
| style="text-align: center; font-weight: bold;" | 1
| Cell 2 || Cell 3
| Circulation Research
| http://circres.ahajournals.org/
| style="text-align: center;" | 11.019
|-
|-
! Row heading A
| style="text-align: center; font-weight: bold;" | 2
|Cell B
| BLOOD
|Cell C
| http://www.bloodjournal.org/
| style="text-align: center;" | 10.452
|-
| style="text-align: center; font-weight: bold;" | 3
| LEUKEMIA
| http://www.nature.com/leu/index.html
| style="text-align: center;" | 10.431
|-
| style="text-align: center; font-weight: bold;" | 4
| Stem Cells
| http://goo.gl/o5cY16
| style="text-align: center;" | 6.523
|-
| style="text-align: center; font-weight: bold;" | 5
| Arteriosclerosis, Thrombosis, and Vascular Biology
| http://atvb.ahajournals.org/
| style="text-align: center;" | 6
|-
| style="text-align: center; font-weight: bold;" | 6
| Haematologica
| http://www.haematologica.org/
| style="text-align: center;" | 5.814
|-
| style="text-align: center; font-weight: bold;" | 7
| The Journal of Thrombosis and Haemostasis
| http://www.isth.org/?page=jth
| style="text-align: center;" | 5.72
|-
| style="text-align: center; font-weight: bold;" | 8
| Blood Reviews
| http://www.bloodreviews.com/
| style="text-align: center;" | 5.565
|-
| style="text-align: center; font-weight: bold;" | 9
| Journal Of Cerebral Blood Flow And Metabolism
| http://www.nature.com/jcbfm/index.html
| style="text-align: center;" | 5.407
|-
| style="text-align: center; font-weight: bold;" | 10
| Thrombosis and Haemostasis
| http://th.schattauer.de/
| style="text-align: center;" | 4.984
|-
| style="text-align: center; font-weight: bold;" | 11
| British Journal of Haematology
| http://goo.gl/s6y3Nl
| style="text-align: center;" | 4.971
|-
| style="text-align: center; font-weight: bold;" | 12
| Journal of Hematology & Oncology
| http://www.jhoonline.org/
| style="text-align: center;" | 4.812
|-
| style="text-align: center; font-weight: bold;" | 13
| Journal of Leukocyte Biology
| http://www.jleukbio.org/
| style="text-align: center;" | 4.289
|-
| style="text-align: center; font-weight: bold;" | 14
| Critical Reviews in Oncology/Hematology
| http://www.croh-online.com/
| style="text-align: center;" | 4.027
|-
| style="text-align: center; font-weight: bold;" | 15
| Current Opinion in Hematology
| http://goo.gl/HhTuub
| style="text-align: center;" | 3.97
|-
| style="text-align: center; font-weight: bold;" | 16
| Seminars in Thrombosis and Hemostasis
| http://goo.gl/z4bTOb
| style="text-align: center;" | 3.876
|-
| style="text-align: center; font-weight: bold;" | 17
| American Journal of Hematology
| http://goo.gl/BpQeOs
| style="text-align: center;" | 3.798
|-
| style="text-align: center; font-weight: bold;" | 18
| Stem Cells and Development
| http://goo.gl/rjmjOd
| style="text-align: center;" | 3.727
|-
| style="text-align: center; font-weight: bold;" | 19
| Bone Marrow Transplantation
| http://www.nature.com/bmt/index.html
| style="text-align: center;" | 3.57
|-
| style="text-align: center; font-weight: bold;" | 20
| Biology of Blood and Marrow Transplantation
| http://www.bbmt.org/
| style="text-align: center;" | 3.404
|}
|}


{| border="5"  cellpadding="5"
{| border="5"  cellpadding="5"
|+ '''GI infection'''
|+ '''GI infection'''
! Pathogen !! Immunocompetent patients !! Immunocompromised patients
! Pathogen !! style="background:#CCFFCC;"|Immunocompetent patients !! style="background:pink"|Immunocompromised patients
|- align="center"
|'''Shigella species''' || [[TMP-SMZ]], 160 and 800 mg, respectively (pediatric dose, 5 and 25 mg/kg, respectively) b.i.d. 3 3 d (if susceptiblea ) or [[fluoroquinolone]] (e.g., 300 mg ofloxacin, 400 mg [[norfloxacin]], or 500 mg [[ciprofloxacin]] b.i.d. 3 3 d); [[nalidixic acid]], 55 mg/kg/d (pediatric) or 1 g/d (adults) 3 5 d [220] or [[ceftriaxone]] azithromycin  || 3 7–10 d
|- align="center"
|- align="center"
|Shigella species || TMP-SMZ, 160 and 800 mg, respectively (pediatric dose, 5 and 25 mg/kg, respectively) b.i.d. 3 3 d (if susceptiblea ) or fluoroquinoloneb (e.g., 300 mg ofloxacin, 400 mg norfloxacin [186], or 500 mg ciprofloxacin b.i.d. 3 3 d) (A-I) [117–121]; nalidixic acid, 55 mg/kg/d (pediatric) or 1 g/d (adults) 3 5 d [220] or ceftriaxone [79]; azithromycin [121] || 3 7–10 d
| width="20%" |'''Non-typhi species of Salmonella''' || Not recommended routinely, but if severe or patient is !6 mo or 150 y old or has prostheses, valvular heart disease, severe atherosclerosis, malignancy, or uremia, [[TMP-SMZ]] (if susceptible) or [[fluoroquinolone]] as above, b.i.d. 3 5–7 d; ceftriaxone, 100 mg/kg/d in 1 or 2 divided doses  || 14 d (or longer if relapsing)
 
|- align="center"
|- align="center"
|Non-typhi species of Salmonella || Not recommended routinely (E-I) [59,60], but if severe or patient is !6 mo or 150 y old or has prostheses, valvular heart disease, severe atherosclerosis, malignancy, or uremia, TMP-SMZ (if susceptible) or fluoroquinoloneb as above, b.i.d. 3 5–7 d (B-III) [29, 132, 221]; ceftriaxone, 100 mg/kg/d in 1 or 2 divided doses [222 || 14 d (or longer if relapsing)
|'''Campylobacter species''' || [[Erythromycin]], 500 mg b.i.d. 3 5 dc  || Same (but may require prolonged treatment)
 
|}

Latest revision as of 16:10, 11 December 2015

Rank Journal Website Impact Factor
1 Circulation Research http://circres.ahajournals.org/ 11.019
2 BLOOD http://www.bloodjournal.org/ 10.452
3 LEUKEMIA http://www.nature.com/leu/index.html 10.431
4 Stem Cells http://goo.gl/o5cY16 6.523
5 Arteriosclerosis, Thrombosis, and Vascular Biology http://atvb.ahajournals.org/ 6
6 Haematologica http://www.haematologica.org/ 5.814
7 The Journal of Thrombosis and Haemostasis http://www.isth.org/?page=jth 5.72
8 Blood Reviews http://www.bloodreviews.com/ 5.565
9 Journal Of Cerebral Blood Flow And Metabolism http://www.nature.com/jcbfm/index.html 5.407
10 Thrombosis and Haemostasis http://th.schattauer.de/ 4.984
11 British Journal of Haematology http://goo.gl/s6y3Nl 4.971
12 Journal of Hematology & Oncology http://www.jhoonline.org/ 4.812
13 Journal of Leukocyte Biology http://www.jleukbio.org/ 4.289
14 Critical Reviews in Oncology/Hematology http://www.croh-online.com/ 4.027
15 Current Opinion in Hematology http://goo.gl/HhTuub 3.97
16 Seminars in Thrombosis and Hemostasis http://goo.gl/z4bTOb 3.876
17 American Journal of Hematology http://goo.gl/BpQeOs 3.798
18 Stem Cells and Development http://goo.gl/rjmjOd 3.727
19 Bone Marrow Transplantation http://www.nature.com/bmt/index.html 3.57
20 Biology of Blood and Marrow Transplantation http://www.bbmt.org/ 3.404
GI infection
Pathogen Immunocompetent patients Immunocompromised patients
Shigella species TMP-SMZ, 160 and 800 mg, respectively (pediatric dose, 5 and 25 mg/kg, respectively) b.i.d. 3 3 d (if susceptiblea ) or fluoroquinolone (e.g., 300 mg ofloxacin, 400 mg norfloxacin, or 500 mg ciprofloxacin b.i.d. 3 3 d); nalidixic acid, 55 mg/kg/d (pediatric) or 1 g/d (adults) 3 5 d [220] or ceftriaxone azithromycin 3 7–10 d
Non-typhi species of Salmonella Not recommended routinely, but if severe or patient is !6 mo or 150 y old or has prostheses, valvular heart disease, severe atherosclerosis, malignancy, or uremia, TMP-SMZ (if susceptible) or fluoroquinolone as above, b.i.d. 3 5–7 d; ceftriaxone, 100 mg/kg/d in 1 or 2 divided doses 14 d (or longer if relapsing)
Campylobacter species Erythromycin, 500 mg b.i.d. 3 5 dc Same (but may require prolonged treatment)
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox_Turky2&oldid=1194085"